This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital \[a tertiary care hospital in Al Ain, UAE\]. The study aims to assess the appropriateness of prescribing apixaban and warfarin in this population and evaluate their safety and effectiveness.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: From date of enrollment until the date of first bleeding event or date of death from any cause, whichever came first, assessed up to 6 months
Effectiveness: VTE
Timeframe: From date of enrollment until the date of first documented VTE event or date of death from any cause, whichever came first, assessed up to 6 months
Effectiveness: Stroke
Timeframe: From date of enrollment until the date of first documented Stroke event or date of death from any cause, whichever came first, assessed up to 6 months